Guest: Nancy M. Holekamp, MD
\n\n Guest: Carl Regillo, MD
\n\n\n \n
This program will deliver much-needed, up-to-date information on evidence-based strategies for dosing available anti-VEGF therapies and for integrating newly approved therapies into practice; with reviews of current clinical data from emerging retinal disease therapies.